Targeting SLC27A2: A Potential Approach To Treating Brain Disorders

Target Name: SLC27A2

NCBI ID: G11001

SLC27A2

Targeting SLC27A2: A Potential Approach To Treating Brain Disorders

SLC27A2 (S27A2_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. It is a member of the solute carrier family 27, which includes proteins that transport and regulate the transport of different molecules across cell membranes. SLC27A2 is characterized by its ability to transport the amino acid glutamic acid across cell membranes, and its role in the regulation of intracellular signaling pathways is still being studied.

One of the key functions of SLC27A2 is its role in the regulation of the blood-brain barrier (BBB), which is a specialized barrier that separates the brain from the surrounding bloodstream. The BBB is designed to protect the brain from harmful substances and to allow only essential nutrients and drugs to enter the brain, while keeping out pathogens and other toxins. SLC27A2 is involved in this process by transporting glutamic acid across the BBB and regulating the movement of other molecules across the barrier.

SLC27A2 has also been shown to be involved in the regulation of cell signaling pathways that are important for brain development and function. For example, SLC27A2 has been shown to be involved in the regulation of the Wnt signaling pathway, which is important for the development and maintenance of neural stem cells. Additionally, SLC27A2 has been shown to be involved in the regulation of the Notch signaling pathway, which is important for the regulation of cell proliferation and differentiation.

SLC27A2 is also known as S27A2, which is a splicing variant of the SLC27A2 gene. S27A2 has been shown to have different expression levels in different tissues of the human body, with higher levels of expression in the brain and lower levels in other tissues. This suggests that S27A2 may be a drug target or biomarker that can be targeted by small molecules or other therapeutic agents.

One approach to targeting S27A2 is to use small molecules that can modulate its activity. For example, researchers have shown that inhibitors of SLC27A2 can reduce the production of glutamic acid in brain cells, which can disrupt the regulation of the BBB and affect brain function. Additionally, researchers have shown that SLC27A2 is involved in the regulation of the blood-brain barrier, so targeting S27A2 may be a way to disrupt the barrier and allow drugs to enter the brain.

Another approach to targeting S27A2 is to use antibodies that can specifically recognize and target the protein. Researchers have shown that antibodies against S27A2 can be used to label the protein in brain cells, which can be used to study its localization and stability. Additionally, antibodies against S27A2 may be used to block its activity in cell signaling pathways, which could be a way to treat diseases that are caused by S27A2-related signaling pathways.

In conclusion, SLC27A2 is a protein that is involved in the regulation of various signaling pathways in the brain. Its role in the regulation of the BBB and the blood-brain barrier, as well as its involvement in the regulation of cell signaling pathways, make it an attractive target for small molecules and antibodies. Further research is needed to fully understand the role of SLC27A2 in the regulation of brain function and to develop effective treatments for diseases that are caused by its activity.

Protein Name: Solute Carrier Family 27 Member 2

Functions: Mediates the import of long-chain fatty acids (LCFA) into the cell by facilitating their transport across cell membranes, playing an important role in hepatic fatty acid uptake (PubMed:20530735, PubMed:22022213, PubMed:24269233, PubMed:10198260, PubMed:10749848, PubMed:11980911). Also functions as an acyl-CoA ligase catalyzing the ATP-dependent formation of fatty acyl-CoA using LCFA and very-long-chain fatty acids (VLCFA) as substrates, which prevents fatty acid efflux from cells and might drive more fatty acid uptake (PubMed:20530735, PubMed:22022213, PubMed:24269233, PubMed:10198260, PubMed:10749848, PubMed:11980911). Plays a pivotal role in regulating available LCFA substrates from exogenous sources in tissues undergoing high levels of beta-oxidation or triglyceride synthesis (PubMed:20530735). Can also activate branched-chain fatty acids such as phytanic acid and pristanic acid (PubMed:10198260). May contribute to the synthesis of sphingosine-1-phosphate (PubMed:24269233). Does not activate C24 bile acids, cholate and chenodeoxycholate (PubMed:11980911). In vitro, activates 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanate (THCA), the C27 precursor of cholic acid deriving from the de novo synthesis from cholesterol (PubMed:11980911). However, it is not critical for THCA activation and bile synthesis in vivo (PubMed:20530735)

The "SLC27A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC27A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets